Literature DB >> 1829504

Complement C3: a molecular mosaic of binding sites.

Z Fishelson1.   

Abstract

Many of the biological activities of the complement system are mediated by C3, the third complement component, and its proteolytic fragments. At the same time, several of the molecules which regulate complement activation target their action at the C3 molecule. Accordingly, the C3 molecule is equipped with multiple binding sites for at least 14 other complement or complement-related proteins. As described in this review, major progress has been made recently in the identification of the C3 binding sites and the residues involved. Yet this has exposed only the "tip of the iceberg". A novel technique which may facilitate the elucidation of the active sites in C3 is presented. Finally, based on the current knowledge on the C3 molecule, a hypothetical model of the molecular organization of this molecule and its binding sites is presented.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829504     DOI: 10.1016/0161-5890(91)90169-k

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

Review 1.  Complement evasion by parasites: search for "Achilles' heel".

Authors:  Z Fishelson
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

2.  IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts.

Authors:  Y Katz; O Nadiv; M J Rapoport; M Loos
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

3.  Co-operation between human CR1 (CD35) and CR2 (CD21) in internalization of their C3b and iC3b ligands by murine-transfected fibroblasts.

Authors:  M L Grattone; C L Villiers; M B Villiers; C Drouet; P N Marche
Journal:  Immunology       Date:  1999-09       Impact factor: 7.397

4.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

5.  Compound heterozygous complement C3 deficiency.

Authors:  Y Katz; R A Wetsel; M Schlesinger; Z Fishelson
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

6.  The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb.

Authors:  Vengadesan Krishnan; Karthe Ponnuraj; Yuanyuan Xu; Kevin Macon; John E Volanakis; Sthanam V L Narayana
Journal:  Structure       Date:  2009-04-15       Impact factor: 5.006

7.  Reduced immune complex binding capacity and increased complement susceptibility of red cells from children with severe malaria-associated anemia.

Authors:  Boaz O Owuor; Collins O Odhiambo; Walter O Otieno; Christine Adhiambo; Dominic W Makawiti; José A Stoute
Journal:  Mol Med       Date:  2008 Mar-Apr       Impact factor: 6.354

8.  IL-13 results in differential regulation of the complement proteins C3 and factor B in tumour necrosis factor (TNF)-stimulated fibroblasts.

Authors:  Y Katz; D Stav; J Barr; J H Passwell
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

9.  Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.

Authors:  C Allen; M Opyrchal; I Aderca; M A Schroeder; J N Sarkaria; E Domingo; M J Federspiel; E Galanis
Journal:  Gene Ther       Date:  2012-08-23       Impact factor: 5.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.